The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Taylor Clark,William Polonsky,Emily Soriano

DOI: https://doi.org/10.1089/dia.2023.0612

2024-03-26

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism

What problem does this paper attempt to address?

Assessing Patterns of CGM use and Metrics of Glycemic Control in T1D and T2D Patients in the Veterans Healthcare System: Integrating CGM Device Data with EHR Data

Tomoki Okuno,Sharon Macwan,Donald Miller,Gregory Norman,Peter Reaven,Jin Zhou

DOI: https://doi.org/10.1089/dia.2024.0083

2024-05-21

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts

Tamara K Oser,Michelle L Litchman,Nancy A Allen,Bethany M Kwan,Lawrence Fisher,Bonnie T Jortberg,William H Polonsky,Sean M Oser

DOI: https://doi.org/10.1007/s11892-021-01408-1

2021-12-09

Abstract:Purpose of review: This article reviews recent clinical efficacy research and economic analysis of the use of personal continuous glucose monitoring (CGM) in type 2 diabetes (T2D). Recent findings: Studies from the past 5 years include a variety of randomized controlled trials, meta-analyses, and other studies which generally favor CGM over self-monitoring of blood glucose (SMBG) in T2D, especially among people with T2D treated with insulin. Concurrently, some studies show no significant difference, but there is no evidence of worse outcomes with CGM. CGM is frequently associated with greater reduction in HbA1c than is SMBG. HbA1c reductions tend to be greater when baseline HbA1c is higher. Reductions in hypoglycemia and hyperglycemia have also been demonstrated with CGM in people with T2D, as have comfort with, preference for, and psychosocial benefits of CGM compared to SMBG. There is a small but growing evidence base on the economics and cost-effectiveness of CGM in T2D. CGM has been clearly demonstrated to have clinical benefits in people with T2D, especially among those treated with insulin. Economic and cost-effectiveness data are more scant but are generally favorable. CGM should be an important consideration in the management of T2D, and its use is likely to increase as efficacy data accumulate further and as costs associated with CGM gradually decrease.
CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Robbe De Groote,Eveline Lefever,Sara Charleer,Phebe Donné,Christophe De Block,Chantal Mathieu,Pieter Gillard

DOI: https://doi.org/10.1089/dia.2023.0616

2024-03-22

Diabetes Technology & Therapeutics

Abstract:Diabetes Technology &Therapeutics, Volume 0, Issue ja, -Not available-.

endocrinology & metabolism
Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring

Tristen Hall,Meredith K Warman,Tamara Oser,Melissa K Filippi,Brian Manning,Jennifer K Carroll,Donald E Nease Jr,Elizabeth W Staton,Sean Oser

DOI: https://doi.org/10.3122/jabfm.2024.240049R1

Abstract:Background: Continuous glucose monitoring (CGM) for patients with type 1 and type 2 diabetes is associated with improved clinical, behavioral, and psychosocial patient health outcomes and is part of the American Diabetes Association's Standards of Medical Care. CGM prescription often takes place in endocrinology practices, yet 50% of adults with type 1 diabetes and 90% of all people with type 2 diabetes receive their diabetes care in primary care settings. This study examined primary care clinicians' perceptions of barriers and resources needed to support CGM use in primary care. Methods: This qualitative study used semistructured interviews with primary care clinicians to understand barriers to CGM and resources needed to prescribe. Participants were recruited through practice-based research networks. Rapid qualitative analysis was used to summarize themes from interview findings. Results: We conducted interviews with 55 primary care clinicians across 21 states. Participants described CGM benefits for patients with varying levels of diabetes self-management and engagement. Major barriers to prescribing included lack of insurance coverage for CGM costs to patients, and time constraints. Participants identified resources needed to foster CGM prescribing, for example, clinician education, support staff, and EHR compatibility. Conclusion: Primary care clinicians face several challenges to prescribing CGM, but they are interested in learning more to help them offer it to their patients. This study reinforces the ongoing need for improved clinician education on CGM technology and continued expansion of insurance coverage for people with both type 1 and type 2 diabetes.
Real-Time Continuous Glucose Monitoring in Type 1 Diabetes: A Qualitative Framework Analysis of Patient Narratives

John C. Pickup,Melissa Ford Holloway,Kritika Samsi

DOI: https://doi.org/10.2337/dc14-1855

2014-12-31

Diabetes Care

Abstract:OBJECTIVE This study analyzed narratives about experiences of real-time continuous glucose monitoring (CGM) in people with type 1 diabetes. RESEARCH DESIGN AND METHODS People with type 1 diabetes using CGM and caregivers completed an online survey. Questions included duration of CGM, frequency of sensor wear, funding, and a free narrative about experiences or views about CGM. We used qualitative framework analysis to analyze 100 responses; 50% of participants were aged ≥18 years. RESULTS Most participants (87%) used CGM with insulin pump therapy, 71% used sensors ≥75% of the time, and 66% received funding for CGM from the National Health Service. Four themes were identified: 1) metabolic control, 2) living with CGM (work and school, sleep, exercise, nutrition, frequency of self-monitoring of blood glucose [SMBG]), 3) psychological issues and patient/caregiver attitudes, and 4) barriers to CGM use (technical issues, financial issues, attitudes of healthcare professionals toward CGM). Despite some hassles, experiences were overwhelmingly positive, with improved glycemic control, diet and exercise management, quality of life, and physical and psychological well-being, as well as reduced frequency of SMBG. Technical problems included sensor inaccuracy and unreliability, and “alarm fatigue.” The advantages of CGM used with an insulin pump with automatic suspension of insulin delivery during hypoglycemia were recorded by several participants, noting reduced hypoglycemia frequency and fear of nocturnal hypoglycemia. CONCLUSIONS Patient and caregiver narratives indicate that CGM is a valuable addition to diabetes care for many with type 1 diabetes.

endocrinology & metabolism
Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

David C Klonoff,Kevin T Nguyen,Nicole Y Xu,Alberto Gutierrez,Juan C Espinoza,Alaina P Vidmar,David C. Klonoff,Kevin T. Nguyen,Nicole Y. Xu,Juan C. Espinoza,Alaina P. Vidmar

DOI: https://doi.org/10.1177/19322968221110830

2022-07-22

Journal of Diabetes Science and Technology

Abstract:Journal of Diabetes Science and Technology, Ahead of Print. Background:Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly.Methods:PubMed and Google Scholar were searched for articles about the use of CGM in individuals without diabetes. Relevant articles that included sufficient details were queried to identify what cohorts of individuals were adopting CGM use and to define trends of use.Results:Four clinical user cases were identified: (1) metabolic diseases related to diabetes with a primary dysregulation of the insulin-glucose axis, (2) metabolic diseases without a primary pathophysiologic derangement of the insulin-glucose axis, (3) health and wellness, and (4) elite athletics. Seven trends in the use of CGM systems in people without diabetes were idenfitied which pertained to both FDA-cleared medical grade products as well as anticipated future products, which may be regulated differently based on intended populations and indications for use.Conclusions:Wearing a CGM has been used not only for diabetes, but with a goal of improving glucose patterns to avoid diabetes, improving mental or physical performance, and promoting motivate healthy behavioral changes. We expect that clinicians will become increasingly aware of (1) glycemic patterns from CGM tracings that predict an increased risk of diabetes, (2) specific metabolic glucotypes from CGM tracings that predict an increased risk of diabetes, and (3) new genetic and genomic biomarkers in the future.

English Else
Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis

Satish K. Garg,Irl B. Hirsch,Enrico Repetto,Janet Snell‐Bergeon,Brian Ulmer,Christopher Perkins,Richard M. Bergenstal

DOI: https://doi.org/10.1111/dom.15866

2024-09-14

Diabetes Obesity and Metabolism

Abstract:Aim The real‐world benefits of continuous glucose monitoring (CGM) in the broad type 2 diabetes (T2D) population are not well studied. Our study evaluated the impact of CGM use on health care resource utilization over 12 months in adults with T2D. Materials and Methods This retrospective cohort analysis used Optum's de‐identified Market Clarity data of >79 million people to evaluate CGM use in people with T2D who were treated with non‐insulin (NIT), basal insulin (BIT) and prandial insulin therapy (PIT). The primary outcomes were changes in all‐cause hospitalizations, acute diabetes‐related hospitalizations and acute diabetes‐related emergency room visits during the 6‐ and 12‐month post‐index period following transition from blood glucose monitoring to CGM. A pre‐specified subgroup analysis assessed glucose control and medication changes among people with T2D over 1 year. Results The analysis included 74 679 adults with T2D (NIT; n = 25 269), (BIT; n = 16 264) and (PIT; n = 33 146). Significant reductions in all‐cause hospitalizations, acute diabetes‐related hospitalizations and acute diabetes‐related emergency room visits were observed in the 6‐month post‐index period that were sustained during the 6–12 month post‐index period (NIT, −10.1%, −31.0%, −30.7%; BIT, −13.9%, −47.6%, −28.2%; and PIT, −22.6%, −52.7%, −36.6%, respectively). A subgroup analysis of 6030 people showed mean glycated haemoglobin reductions at approximately 3 months, which were also sustained throughout the post‐index period: NIT, −1.1 (0.05)%; BIT, −1.1 (0.06)%; and PIT, −0.9 (0.04)%, p

endocrinology & metabolism
Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes

R. A. Ajjan,S. Seidu,J. P. Riveline

DOI: https://doi.org/10.1007/s13300-024-01607-5

2024-06-23

Diabetes Therapy

Abstract:Continuous glucose monitoring (CGM) is now advocated for the clinical management of individuals with type 1 diabetes (T1D). However, this glucose monitoring strategy is not routinely used in type 2 diabetes (T2D), given the large population, significant cost implications and relatively limited supporting evidence. T2D is a more heterogenous condition compared with T1D with various glucose lowering therapies that do not necessarily require CGM to ensure within target glucose levels. While all individuals with T2D may benefit from CGM at certain time points, the whole T2D population does not necessarily require this technology continuously, which should be prioritized based on patient benefit and cost effectiveness. In this pragmatic opinion piece, we describe the rationale and evidence for CGM use in different subgroups of individuals with T2d, divided according to the stage of the condition, glycemic therapies, presence of diabetes complications, or associated co-morbidities. We discuss a total of 16 T2D subgroups and provide a clinical view on CGM use in each, based on current evidence while also highlighting areas of knowledge gaps. This work provides health care professionals with a simple guide to CGM use in different T2D groups and gives suggestion for future studies to justify expansion of this technology.

endocrinology & metabolism
Exploring the Initial Encounter with Continuous Glucose Monitoring among Individuals with Type 2 Diabetes: A Two-Week Trip

Miseon Shin,Youngran Yang,Jeong Hee Kang,Heung Yong Jin

DOI: https://doi.org/10.2147/DMSO.S466734

2024-09-20

Abstract:Purpose: This study aimed to explore the inaugural experience of using a continuous glucose monitoring (CGM) system in patients with type 2 diabetes. Patients and methods: This study employed a qualitative design. Thirty-one patients with type 2 diabetes were recruited from a national university hospital and underwent CGM for two weeks. Individual interviews with 28 participants were conducted between August 1 and October 17, 2022, after the CGM. Thematic analysis was used to examine the data. Results: The results revealed transformative shifts in aspects of participants' lives due to CGM use, including alterations in dietary management and interpersonal relationships. During the two-week journey with CGM, participants were able to visually observe exercise effects and other benefits, leading to the discovery of a new utility for this innovative medical device. However, unavoidable drawbacks such as high cost, inaccurate results, and skin irritation have been identified, prompting suggestions for improvement. Conclusion: This study determined that CGM is both feasible and valuable for facilitating lifestyle adjustments to manage diabetes. Nevertheless, the challenge of discomfort associated with CGM use should be addressed in the future. To ensure effective utilization and overcome potential obstacles, it is recommended that a comprehensive and user-friendly CGM education manual be created, with the scope of CGM insurance coverage extended to include this research in the future.
Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes

Shweta Pathak,Kristina Kearin,Anna R Kahkoska,Kathryn A Fuller,Bradley Staats,Joseph Albright,Til Stürmer,John B Buse,Benjamin Y Urick

DOI: https://doi.org/10.1089/dia.2022.0418

Abstract:Background: Despite increased use of continuous glucose monitoring (CGM) systems, studies to quantify patterns of CGM use are limited. In December 2018, a policy change by a commercial insurer expanded coverage of CGM through the pharmacy benefit, creating an opportunity to evaluate the impact of this change on CGM utilization. Research Design and Methods: Pharmacy and medical claims from 2016 to 2020 were used to estimate the prevalence of CGM use among insulin users with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) before and after the policy change. Change in CGM use was assessed using an interrupted time series design. Results: At the beginning of the study period, 18.8% of T1DM patients and 1.2% of T2DM patients used CGM. Use rose to 30.5% and 6.6% in the quarter before the policy change. The policy resulted in an immediate 9.5% (P < 0.0001) and 2.8% (P < 0.0001) change in use and increased the rate of quarterly change by 0.5% (P = 0.002) and 0.8% (P < 0.0001). At the end of the study period, 58.2% and 14.9% of T1DM and T2DM patients used CGM. Conclusion: CGM use significantly increased after addition to the pharmacy benefit. Rate of change in CGM use was lower in T1DM compared to the T2DM population, but overall use remained higher among patients with T1DM. Increased CGM use in the population studied aligns with those whose clinical guidelines suggest would most likely benefit. Additional work is needed to evaluate the impact of this benefit change on health care spending and outcomes.
Continuous glucose monitoring for primary care patients with diabetes: Barriers, facilitators, & resources to support access

Meredith Warman,Melissa Fillippi,Brian Manning,Tamara Oser,Donald Nease,Tristen Hall,Sean Oser,Jennifer Carroll

DOI: https://doi.org/10.1370/afm.20.s1.2689

2022-04-01

Abstract:Context: Continuous glucose monitoring (CGM) for patients with type 1 and type 2 diabetes is associated with improved patient health outcomes including reduced glycated hemoglobin (A1c) and hypoglycemia and is part of ADA Standards of Medical Care. CGM prescription often takes place in endocrinology practices. With limited access to endocrinologists, many patients could benefit from receiving CGM through primary care. Objective: The overall study aims to understand primary care clinicians' CGM prescribing experience and likelihood to prescribe, and identify resources needed to support prescribing CGM. This qualitative phase examines barriers and facilitators to prescribing, and resources to support prescribing. Study Design: Qualitative phase of an explanatory sequential mixed-methods study following a cross-sectional online survey. Respondents were invited to participate in phone/virtual interviews to understand CGM prescribing attitudes and behaviors. Participants were stratified based on factors related to distance to an endocrinologist and prescribing behavior. Rapid qualitative analysis was used to understand relationships and trends, and identify resources to support CGM prescription in primary care. Setting: Two primary care research networks. Population studied: Primary care physicians and advanced practice providers in the U.S. Outcome Measures: Resources needed, barriers, and facilitators to prescribing CGM. Results: 55 interviews were conducted. The following themes emerged in the analysis: Insurance and cost-related barriers were most commonly cited, as well as distance to endocrinology when > 40 miles away. Facilitators included training and experience with CGM and staff to support patient education and insurance navigation. Resources (e.g., webinars, online guides, conferences) to increase knowledge about CGM use and clinical outcomes and guidance with insurance processes/coverage could support CGM prescription in primary care. Conclusions: Increased understanding among primary care clinicians of the use and benefits of CGM can help with confidence in prescribing. CGM management in primary care could benefit patients with diabetes, especially those with access barriers to endocrinologists. Addressing cost and insurance barriers at a policy level can make CGM more attainable to underserved populations and reduce disparities in diabetes control.
Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications

Agata Chobot,Claudia Piona,Bruno Bombaci,Olga Kamińska-Jackowiak,Valentina Mancioppi,Stefano Passanisi

DOI: https://doi.org/10.3390/children11080907

2024-07-27

Abstract:Continuous glucose monitoring (CGM) systems, including real-time CGM and intermittently scanned CGM, have revolutionized diabetes management, particularly in children and adolescents with type 1 diabetes (T1D). These systems provide detailed insights into glucose variability and detect asymptomatic and nocturnal hypoglycemia, addressing limitations of traditional self-monitoring blood glucose methods. CGM devices measure interstitial glucose concentrations constantly, enabling proactive therapeutic decisions and optimization of glycemic control through stored data analysis. CGM metrics such as time in range, time below range, and coefficient of variation are crucial for managing T1D, with emerging metrics like time in tight range and glycemia risk index showing potential for enhanced glycemic assessment. Recent advancements suggest the utility of CGM systems in monitoring the early stages of T1D and individuals with obesity complicated by pre-diabetes, highlighting its therapeutic versatility. This review discusses the current CGM systems for T1D during the pediatric age, established and emerging metrics, and future applications, emphasizing the critical role of CGM devices in improving glycemic control and clinical outcomes in children and adolescents with diabetes.
Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence

Samuel Seidu,Setor K. Kunutsor,Ramzi A. Ajjan,Pratik Choudhary

DOI: https://doi.org/10.2337/dc23-1520

2024-01-16

Diabetes Care

Abstract:BACKGROUND Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. PURPOSE To assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D. DATA SOURCES We conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. STUDY SELECTION We analyzed studies meeting these criteria: randomized controlled trials (RCT) with comparison of at least two interventions for ≥8 weeks in T2D patients, including CGM in real-time/retrospective mode, short-/long-term CGM, isCGM, and SMBG, reporting glycemic and relevant data. DATA EXTRACTION We used a standardized data collection form, extracting details including author, year, study design, baseline characteristics, intervention, and outcomes. DATA SYNTHESIS We included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D (CGM 632 vs. usual care/SMBG 514 and isCGM 871 vs. usual care/SMBG 766). CGM reduced HbA 1c (mean difference −0.19% [95% CI −0.34, −0.04]) and glycemic medication effect score (−0.67 [−1.20 to −0.13]), reduced user satisfaction (−0.54 [−0.98, −0.11]), and increased the risk of adverse events (relative risk [RR] 1.22 [95% CI 1.01, 1.47]). isCGM reduced HbA 1c by −0.31% (−0.46, −0.17), increased user satisfaction (0.44 [0.29, 0.59]), improved CGM metrics, and increased the risk of adverse events (RR 1.30 [0.05, 1.62]). Neither CGM nor isCGM had a significant impact on body composition, blood pressure, or lipid levels. LIMITATIONS Limitations include small samples, single-study outcomes, population variations, and uncertainty for younger adults. Additionally, inclusion of <10 studies for most end points restricted comprehensive analysis, and technological advancements over time need to be considered. CONCLUSIONS Both CGM and isCGM demonstrated a reduction in HbA 1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.

endocrinology & metabolism
Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review

Pennie J Taylor,Campbell H Thompson,Grant D Brinkworth

DOI: https://doi.org/10.1111/jdi.12807

2018-03-01

Journal of Diabetes Investigation

Abstract:The present narrative review discusses the role of continuous glucose monitoring (CGM) in glycemic and weight control, and lifestyle behavior adherence in adults with type 2 diabetes. A literature search from January 2001 to November 2017 was carried out (MEDLINE, CINAHL, Web of Science and Scopus). Eligible studies were trials evaluating the use of CGM with the aim of achieving glucose control or lifestyle-related treatment adherence over a period of ≥8 weeks in adults with type 2 diabetes compared with usual care or another comparison intervention, or observational trials reporting CGM user experience. A total of 5,542 participants were recruited into 11 studies (eight randomized controlled trials [n = 5,346] and three observational studies [n = 196]). The sample size ranged 6-4,678 participants, the mean age was 51.7-60.0 years and diabetes duration was 2.1-19.2 years, with high heterogeneity between studies. Overall, the available evidence showed, compared with traditional self-monitoring of blood glucose levels, CGM promoted greater reductions in glycated hemoglobin, bodyweight and caloric intake; higher adherence rating to a personal eating plan; and increases in physical activity. High compliance to CGM wear-time and device calibration was reported (>90%). The addition of lifestyle and/or behavioral counseling to CGM appeared to further potentiate these improvements. Preliminary evidence suggests that CGM use promotes glycemic and weight control, and lifestyle behavior adherence in adults with type 2 diabetes. These benefits might be further enhanced with integration of diet, exercise, and glucose excursion education and counseling. However, specific attributes of effective interventions and the application of CGM information for promoting improved outcomes and healthier choices remain unclear.

endocrinology & metabolism
Use of continuous glucose monitor as a motivational device for lifestyle modifications to improve glycaemic control in patients with type 2 diabetes treated with non-insulin therapies

Hisham Ahmed Farhan,Khulood Bukhari,Navneet Grewal,Sranita Devarasetty,Kashif Munir

DOI: https://doi.org/10.1136/bcr-2021-248579

2022-06-07

Abstract:The efficacy of continuous glucose monitors (CGM) to improve glycaemic control in individuals on intensive insulin therapy (basal and prandial) has been well established in several studies; however, there is limited evidence on its usage and efficacy in patients with type 2 diabetes (T2D) who are on non-insulin therapies. Lifestyle modifications and glucose monitoring are essential components of the management of T2D. We report a case that demonstrates the impact of CGM use as an effective tool for patient education and motivation to implement and adhere to lifestyle modifications in improving glycaemic control in a patient with long-standing poorly controlled T2D who was on oral glucose-lowering medications. CGM use is associated with high level of patient satisfaction which can improve quality of life and has the potential to reduce long-term complications related to poor glycaemic control. These observations emphasise the need to broaden the use of CGM in this patient population.
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino,Thomas Danne,Richard M. Bergenstal,Stephanie A. Amiel,Roy Beck,Torben Biester,Emanuele Bosi,Bruce A. Buckingham,William T. Cefalu,Kelly L. Close,Claudio Cobelli,Eyal Dassau,J. Hans DeVries,Kim C. Donaghue,Klemen Dovc,Francis J. Doyle,Satish Garg,George Grunberger,Simon Heller,Lutz Heinemann,Irl B. Hirsch,Roman Hovorka,Weiping Jia,Olga Kordonouri,Boris Kovatchev,Aaron Kowalski,Lori Laffel,Brian Levine,Alexander Mayorov,Chantal Mathieu,Helen R. Murphy,Revital Nimri,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,David Rodbard,Banshi Saboo,Desmond Schatz,Keaton Stoner,Tatsuiko Urakami,Stuart A. Weinzimer,Moshe Phillip

DOI: https://doi.org/10.2337/dci19-0028

2019-06-08

Diabetes Care

Abstract:Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

endocrinology & metabolism
Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non–Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data

Robert Dowd,Lauren H Jepson,Courtney R Green,Gregory J Norman,Roy Thomas,Keri Leone

DOI: https://doi.org/10.2196/43991

2023-01-18

JMIR Diabetes

Abstract:Background: The benefits of real-time continuous glucose monitoring (RT-CGM) are well established for patients with type 1 diabetes (T1D) and patients with insulin-treated type 2 diabetes (T2D). However, the usage and effectiveness of RT-CGM in the context of non–insulin-treated T2D has not been well studied. Objective: We aimed to assess glycemic metrics and rates of RT-CGM feature utilization in users with T1D and non–insulin-treated T2D. Methods: We retrospectively analyzed data from 33,685 US-based users of an RT-CGM system (Dexcom G6; Dexcom, Inc) who self-identified as having either T1D (n=26,706) or T2D and not using insulin (n=6979). Data included glucose concentrations, alarm settings, feature usage, and event logs. Results: The T1D cohort had lower proportions of glucose values in the 70 mg/dl to 180 mg/dl range than the T2D cohort (52.1% vs 70.8%, respectively), with more values indicating hypoglycemia or hyperglycemia and higher glycemic variability. Discretionary alarms were enabled by a large majority in both cohorts. The data sharing feature was used by 38.7% (10,327/26,706) of those with T1D and 10.4% (727/6979) of those with T2D, and the mean number of followers was higher in the T1D cohort. Large proportions of patients with T1D or T2D enabled and customized their glucose alerts. Retrospective analysis features were used by the majority in both cohorts (T1D: 15,783/26,706, 59.1%; T2D: 3751/6979, 53.8%). Conclusions: Similar to patients with T1D, patients with non–insulin-treated T2D used RT-CGM system features, suggesting beneficial, routine engagement with data by patients and others involved in their care. Motivated patients with diabetes could benefit from RT-CGM coverage.
564-P: Insights into How Health Technologies Can Support Patient-Centered Diabetes Self-Management—A Mixed-Methods Approach

TIMOTHY M. BOBER,JODI S. KRALL,SOPHIA GARVIN,MARGARET ZUPA,CHRISTINA WHITE,BHAVINI SOTAA,CARISSA LOW,ANN-MARIE ROSLAND

DOI: https://doi.org/10.2337/db24-564-p

IF: 7.7

2024-06-14

Diabetes

Abstract:Background & Objective: New technologies like mobile applications (apps), activity trackers, and continuous glucose monitors (CGM) are available to support people with diabetes (PWD), but it is not clear how these tools are currently used together for diabetes self-management (DSM). This mixed methods study assessed how PWD use technology to relate diabetes self-care behaviors to DSM goals. Methods: Sixty-one adults aged 18-75 with type I or II diabetes (DM) who used ≥1 diabetes medication were surveyed about health app and monitor use (glucose, food, exercise/activity, weight, sleep, and stress trackers) as well as digital and general health literacy. 18 survey respondents completed semi-structured interviews examining how technologies were and could be used in daily DSM. Results: Survey respondents were 34% African American and 38% female, 48% were >45 years old. Regarding DM type and treatment, 72% had Type II diabetes, 59% used insulin, and 56% had used CGMs. Participants had high levels of digital and general health literacy. For tech use, 87% of respondents used ≥1 health app; 59% had used an activity tracker; and 47% had used apps to track ≥3 separate health behaviors. While glucose-tracking apps were more common among CGM (92%) and insulin users (100%), survey respondents used other health apps at similar rates regardless of CGM (57% vs. 60%) or insulin status (61% vs. 60%). Interviewees described using glucose-tracking apps to personalize dietary choices, but less often reported using data from other health apps or monitors for DSM goals. For data to be helpful for DSM, interviewees desired data that was passively collected, easily integrated across monitors, easily visualized, and tailorable to personal health goals. Conclusion: PWD reported using apps to monitor multiple behaviors that impact DSM. Findings suggest that there are untapped opportunities to integrate diabetes apps with trackable lifestyle data to support patient-centered DSM. Disclosure T.M. Bober: None. J.S. Krall: Research Support; Becton, Dickinson and Company, Sanofi. S. Garvin: None. M. Zupa: None. C. White: None. B. Sotaa: None. C. Low: None. A. Rosland: None. Funding The Pittsburgh Foundation (MR2022-128717)

endocrinology & metabolism
Technology and Continuous Glucose Monitoring Access, Literacy, and Use Among Patients at the Diabetes Center of an Inner-City Safety-Net Hospital: Mixed Methods Study

Gaëlle Sabben,Courtney Telfort,Marissa Morales,Wenjia Stella Zhang,Juan C Espinoza,Francisco J Pasquel,Kate Winskell

DOI: https://doi.org/10.2196/54223

2024-10-15

JMIR Diabetes

Abstract:Background: Despite the existence of an increasing array of digital technologies and tools for diabetes management, there are disparities in access to and uptake and use of continuous glucose monitoring (CGM) devices, particularly for those most at risk of poor diabetes outcomes. Objective: This study aims to assess communication technology and CGM access, literacy, and use among patients receiving treatment for diabetes at an inner-city safety-net hospital. Methods: A survey on digital technology ownership and use was self-administered by 75 adults with type 1 and type 2 diabetes at the diabetes clinic of Grady Memorial Hospital in Atlanta, Georgia. In-depth interviews were conducted with 16% (12/75) of these patient participants and 6 health care providers (HCPs) to obtain additional insights into the use of communication technology and CGM to support diabetes self-management. Results: Most participants were African American (66/75, 88%), over half (39/75, 52%) were unemployed or working part time, and 29% (22/75) had no health insurance coverage, while 61% (46/75) had federal coverage. Smartphone ownership and use were near universal; texting and email use were common (63/75, 84% in both cases). Ownership and use of tablets and computers and use and daily use of various forms of media were more prevalent among younger participants and those with type 1 diabetes, who also rated them as easier to use. Technology use specifically for diabetes and health management was low. Participants were supportive of a potential smartphone app for diabetes management, with a high interest in such an app helping them track blood sugar levels and communicate with their care teams. Younger participants showed higher levels of interest, perceived value, and self-efficacy for using an app with these capabilities. History of CGM use was reported by 56% (42/75) of the participants, although half (20/42, 48%) had discontinued use, above all due to the cost of the device and issues with its adhesive. Nonuse was primarily due to not being offered CGM by their HCP. Reasons given for continued use included convenience, improved blood glucose control, and better tracking of blood glucose. The in-depth interviews (n=18) revealed high levels of satisfaction with CGM by users and supported the survey findings regarding reasons for continued use. They also highlighted the value of CGM data to enhance communication between patients and HCPs. Conclusions: Smartphone ownership was near universal among patients receiving care at an inner-city hospital. Alongside the need to address barriers to CGM access and continued use, there is an opportunity to leverage increased access to communication technology in combination with CGM to improve diabetes outcomes among underresourced populations.
Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic

Swantje Kannenberg,Jenny Voggel,Nils Thieme,Oliver Witt,Kim Lina Pethahn,Morten Schütt,Christian Sina,Guido Freckmann,Torsten Schröder

DOI: https://doi.org/10.1177/19322968241266821

2024-07-30

Abstract:Background: We present a digital therapeutic (DTx) using continuous glucose monitoring (CGM) and an advanced artificial intelligence (AI) algorithm to digitally personalize lifestyle interventions for people with type 2 diabetes (T2D). Method: A study of 118 participants with non-insulin-treated T2D (HbA1c ≥ 6.5%) who were already receiving standard care and had a mean baseline (BL) HbA1c of 7.46% (0.93) used the DTx for three months to evaluate clinical endpoints, such as HbA1c, body weight, quality of life and app usage, for a pre-post comparison. The study also included an assessment of initial long-term data from a second use of the DTx. Results: After three months of using the DTx, there was an improvement of 0.67% HbA1c in the complete cohort and -1.08% HbA1c in patients with poorly controlled diabetes (BL-HbA1c ≥ 7.0%) compared with standard of care (P < .001). The number of patients within the therapeutic target range (< 7.0%) increased from 38% to 60%, and 33% were on the way to remission (< 6.5%). Patients who used the DTx a second time experienced a reduction of -0.76% in their HbA1c levels and a mean weight loss of -6.84 kg after six months (P < .001) compared with BL. Conclusions: These results indicate that the DTx has clinically relevant effects on glycemic control and weight reduction for patients with both well and poorly controlled diabetes, whether through single or repeated usage. It is a noteworthy improvement in T2D management, offering a non-pharmacological, fully digital solution that integrates biofeedback through CGM and an advanced AI algorithm.

The Potential Impact of CGM Use on Diabetes-Related Attitudes and Behaviors in Adults with T2D: A Qualitative Investigation of the Patient Experience

Assessing Patterns of CGM use and Metrics of Glycemic Control in T1D and T2D Patients in the Veterans Healthcare System: Integrating CGM Device Data with EHR Data

Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts

CGM-derived glucometrics in adults with type 1 diabetes when switching basal insulins.

Clinician-Reported Barriers and Needs for Implementation of Continuous Glucose Monitoring

Real-Time Continuous Glucose Monitoring in Type 1 Diabetes: A Qualitative Framework Analysis of Patient Narratives

Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis

Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes

Exploring the Initial Encounter with Continuous Glucose Monitoring among Individuals with Type 2 Diabetes: A Two-Week Trip

Impact of Expanding Access to Continuous Glucose Monitoring Systems Among Insulin Users with Type 1 or Type 2 Diabetes

Continuous glucose monitoring for primary care patients with diabetes: Barriers, facilitators, & resources to support access

Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications

Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence

Effectiveness and acceptability of continuous glucose monitoring for type 2 diabetes management: A narrative review

Use of continuous glucose monitor as a motivational device for lifestyle modifications to improve glycaemic control in patients with type 2 diabetes treated with non-insulin therapies

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non–Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data

564-P: Insights into How Health Technologies Can Support Patient-Centered Diabetes Self-Management—A Mixed-Methods Approach

Technology and Continuous Glucose Monitoring Access, Literacy, and Use Among Patients at the Diabetes Center of an Inner-City Safety-Net Hospital: Mixed Methods Study

Unlocking Potential: Personalized Lifestyle Therapy for Type 2 Diabetes Through a Predictive Algorithm-Driven Digital Therapeutic